Jupiter, Fla., October 9, 2014/PR Newswire/ – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has filed Amendment No. 2 to its Form 10 Registration Statement with the U.S. Securities and Exchange Commission (the “SEC”) in response to their comment letter dated September 11, 2014.
The Amended Form 10 Registration Statement includes updated information about Dyadic and enhanced disclosures regarding our business processes, our current and future opportunities and prospects, and clarifies certain risks to be considered when considering investing in Dyadic.
“The filing of our Amended Form 10 and the corresponding response to the SEC’s comment letter further demonstrates Dyadic’s commitment to becoming a fully reporting SEC company, and is another significant milestone to this end.” said Mark Emalfarb, Chairman and CEO of Dyadic. “As we have said in the past, we believe when investors have a chance to read through our Form 10 and fully understand the power of our patented and proprietary C1 Expression System, they will realize the untapped potential of turning DNA into enzymes and other protein products. Our focus has been on perfecting a method for turning DNA into high quality consumer products, and our C1 Expression System allows us to do this on a large scale and at low cost. The Form 10 clarifies our market position, provides a sampling of the opportunities on which Dyadic and its licensees are focused.”
Upon the effectiveness of the Registration Statement on Form 10, Dyadic will be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, and as a result will file periodic reports and other information with the SEC. The Registration Statement on Form 10 is available on the SEC’s website at www.sec.gov and on Dyadic’s website at www.dyadic.com.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 Expression System can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic’s website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain statements in this press release may contain “forward-looking statements” about Dyadic and its industry that involve substantial risks and uncertainties. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements about Dyadic’s beliefs and expectations regarding its technology platform, its licensing strategy, its collaboration and licensing agreements, its ability to commercialize its products and achieve further growth, its ability to continue past success, its ability to register its securities with the SEC and the potential and value of its C1 Expression System as well as words such as “anticipates,” “believes,” “estimates,” “expects,” “forecasts,” “intends,” “plans,” “projects,” “may,” “will,” “should,” and other similar expressions may constitute forward-looking statements. These forward-looking statements reflect Dyadic’s views regarding future events and financial performance. Such statements are subject to risks, uncertainties, assumptions and other important factors, many of which may be beyond Dyadic’s control that could cause actual results to differ materially from anticipated results. If Dyadic’s assumptions and estimates are incorrect, or if Dyadic becomes subject to significant limitations as the result of litigation or regulatory action, then Dyadic’s actual results could vary materially from those expressed or implied in these forward-looking statements. The forward-looking statements are and will be based on Dyadic’s then current views and assumptions regarding future events and speak only as of their dates made. Dyadic assumes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. For further information regarding risks and uncertainties associated with Dyadic’s business, please refer to the “Risk Factors” section of Dyadic’s Registration Statement on Form 10 filed with the U.S. Securities and Exchange Commission on August 15, 2014.
Investor Relations Contact:
Dyadic International, Inc.
Michael J. Faby
Vice President of Finance